H.Res. 280 · 117th Congress
Expressing the sense of the House of Representatives that decades of policies rooted in socialism have…
Full title
Expressing the sense of the House of Representatives that decades of policies rooted in socialism have stifled United States domestic pharmaceutical drug manufacturing and left the United States exposed to the hostile actions and unfair trade practices of the People's Republic of China.
Key: what the circles and colors mean
Each circle is a bill. The ring fills as it moves through Congress:
Under the number: the Yea · Nay count of its final (or latest) recorded vote. On a member's page, the small badge is how that member voted: Y Yea / Aye, N Nay / No, P Present, – Not voting.
Gold and violet are only for Yea and Nay; they never mean a party. A member's party is the letter on their photo.
Never voted on. It didn't reach a floor vote before the 117th Congress ended, so it expired. A bill has to be introduced again to be considered in a new Congress.
R
JacksonSponsor14 cosponsors · 14 R
R
Banks
JB
R
Baird
CF
R
Franklin
JH
R
Hice
YH
R
Herrell
TM
R
McClintock
BM
R
Mast
CR
R
Roy
MS
R
Salazar
CT
R
Tenney
DH
R
Harshbarger
JC
R
Carter
JR
R
Rutherford
VS
R
Spartz10 signed on when it was introduced; the rest joined later. Cosponsors who withdrew aren't shown.
This resolution commits to the use of competitive free market and free trade policies to combat national security threats caused by China and its attacks on the U.S. pharmaceutical manufacturing base.
What it does: CRS summary · Introduced in House · Mar 26, 2021
This resolution commits to the use of competitive free market and free trade policies to combat national security threats caused by China and its attacks on the U.S. pharmaceutical manufacturing base.
The resolution urges the United States to (1) remove tax, regulatory, and debt burdens and barriers that have weakened this base; (2) empower the U.S. Trade Representative to take specified actions to counter harmful and unfair trade practices by China; (3) address shortcomings in Food and Drug Administration data collection related to foreign-sourced pharmaceutical ingredients; and (4) identify and streamline regulatory hurdles that have impeded the U.S. pharmaceutical manufacturing base.
Written by the nonpartisan Congressional Research Service. All summary versions on Congress.gov
About this bill and sources
Official title: Expressing the sense of the House of Representatives that decades of policies rooted in socialism have stifled United States domestic pharmaceutical drug manufacturing and left the United States exposed to the hostile actions and unfair trade practices of the People's Republic of China.
Latest action (Mar 29, 2021): Referred to the Subcommittee on Health.
Policy area: Foreign Trade and International Finance · Origin: House · Introduced: Mar 26, 2021
Official page on Congress.gov · Bill text (GovInfo) · Status record (XML)
No recorded floor vote found.